Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 20Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Melanoma 3Lymphoma 3Lung Neoplasms 3Hematologic Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Recurrence 2Neoplasms 2Multiple Myeloma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Leukemia 2Healthy Participants 2Disease Progression 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1

Interventions

Fulvestrant 2vistusertib 1proto-oncogene protein c-fes-fps 1capivasertib 1Transurethral Resection of Bladder 1Hydroxychloroquine 1Everolimus 1Estrogens 1Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Estrogen Receptor Positive Breast Cancer × capivasertib × Clear all
NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡